This company has been acquired
G1 Therapeutics Past Earnings Performance
Past criteria checks 0/6
G1 Therapeutics has been growing earnings at an average annual rate of 9.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 38.8% per year.
Key information
9.2%
Earnings growth rate
14.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 38.8% |
| Return on equity | -182.1% |
| Net Margin | -76.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Jul 26
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Jun 24Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22Revenue & Expenses Breakdown
How G1 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 58 | -45 | 61 | 29 |
| 31 Mar 24 | 84 | -31 | 65 | 35 |
| 31 Dec 23 | 83 | -48 | 72 | 43 |
| 30 Sep 23 | 78 | -71 | 80 | 52 |
| 30 Jun 23 | 89 | -78 | 88 | 63 |
| 31 Mar 23 | 57 | -126 | 96 | 72 |
| 31 Dec 22 | 51 | -148 | 101 | 83 |
| 30 Sep 22 | 47 | -154 | 101 | 86 |
| 30 Jun 22 | 28 | -171 | 101 | 87 |
| 31 Mar 22 | 24 | -171 | 100 | 85 |
| 31 Dec 21 | 31 | -148 | 96 | 75 |
| 30 Sep 21 | 42 | -134 | 98 | 72 |
| 30 Jun 21 | 64 | -103 | 92 | 69 |
| 31 Mar 21 | 60 | -95 | 81 | 68 |
| 31 Dec 20 | 45 | -99 | 69 | 72 |
| 30 Sep 20 | 29 | -109 | 57 | 81 |
| 30 Jun 20 | 2 | -130 | 50 | 127 |
| 31 Mar 20 | 0 | -130 | 44 | 109 |
| 31 Dec 19 | 0 | -122 | 41 | 88 |
| 30 Sep 19 | 0 | -111 | 35 | 135 |
| 30 Jun 19 | 0 | -99 | 29 | 70 |
| 31 Mar 19 | 0 | -89 | 23 | 53 |
| 31 Dec 18 | 0 | -85 | 19 | 70 |
| 30 Sep 18 | 0 | -78 | 14 | 0 |
| 30 Jun 18 | 0 | -74 | 11 | 0 |
| 31 Mar 18 | 0 | -68 | 9 | 17 |
| 31 Dec 17 | 0 | -65 | 7 | 54 |
| 30 Sep 17 | 0 | -60 | 6 | 0 |
| 30 Jun 17 | 0 | -52 | 5 | 0 |
| 31 Mar 17 | 0 | -45 | 4 | 0 |
| 31 Dec 16 | 0 | -35 | 5 | 0 |
| 31 Dec 15 | 1 | -22 | 3 | 0 |
| 31 Dec 14 | 1 | -7 | 3 | 0 |
Quality Earnings: GTHX is currently unprofitable.
Growing Profit Margin: GTHX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GTHX is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.
Accelerating Growth: Unable to compare GTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GTHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: GTHX has a negative Return on Equity (-182.05%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/18 12:42 |
| End of Day Share Price | 2024/09/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
G1 Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harshita Polishetty | B. Riley Securities, Inc. |
| Dane Leone | BTIG |
| Charles Butler | D. Boral Capital LLC. |